SCHEMBL1665859

SCHEMBL1665859

CC(C)CC(=O)Oc1ccc(C=O)cc1

nearest known ligand 0.62

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.62
ALDH1A3 P47895 1/20 0.50
ALDH1A1 P00352 6/20 0.48
CYP2A6 P11509 1/20 0.46
MIF P14174 1/20 0.45
ALOX15 P16050 1/20 0.43
MAPT P10636 2/20 0.42
LMNA P02545 1/20 0.42
HTT P42858 1/20 0.42
HSD17B10 Q99714 1/20 0.42
TYR P14679 1/20 0.41
PARP10 Q53GL7 1/20 0.41
PARP3 Q9Y6F1 1/20 0.41
KDM4E B2RXH2 1/20 0.41
ESR1 P03372 1/20 0.40
HIF1A Q16665 1/20 0.40
ELANE P08246 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23020849 0.85 MIF (0.44) KMT2AALDH1A1MIFALOX15MAPT
SCHEMBL1564782 0.80 KMT2A (0.68) KMT2AALDH1A3ALDH1A1CYP2A6MAPT
SCHEMBL6177060 0.80 GAA (0.53) KMT2AALDH1A1ALOX15MAPTLMNA
SCHEMBL1532609 0.80 LMNA (0.53) KMT2AALDH1A1ALOX15MAPTLMNA
SCHEMBL13481050 0.80 KMT2A (0.85) KMT2AALDH1A3ALDH1A1CYP2A6MAPT
SCHEMBL29325146 0.80 KMT2A (0.72) KMT2AALDH1A3ALDH1A1CYP2A6MAPT
SCHEMBL16443965 0.79 ALDH1A1 (0.47) KMT2AALDH1A1MIFALOX15MAPT
SCHEMBL10518649 0.79 KMT2A (0.47) KMT2AALDH1A1ALOX15MAPTLMNA
SCHEMBL3512372 0.79 GAA (0.50) KMT2AALDH1A1ALOX15MAPTLMNA
SCHEMBL23318140 0.79 ALDH1A1 (0.47) KMT2AALDH1A1ALOX15MAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250135059-A1 COMPOSITIONS COMPRISING FRAGRANCE MATERIALS THE PROCTER & GAMBLE COMPANY 2025-05-01 US disclosed
EP-2493905-B1 BISPHOSPHONATE COMPOUNDS FOR TREATING BONE METABOLISM DISORDERS WARNER CHILCOTT CO LLC (PR) 2016-11-30 EP disclosed
US-8822435-B2 Bisphosphonate compounds WARNER CHILCOTT COMPANY, LLC (US) 2014-09-02 US disclosed
US-20140194389-A1 BISPHOSPHONATE COMPOUNDS WARNER CHILCOTT COMPANY, LLC (US) 2014-07-10 US disclosed
US-8710215-B2 Bisphosphonate compounds WARNER CHILCOTT COMPANY, LLC (US) 2014-04-29 US disclosed
US-20130035482-A1 BISPHOSPHONATE COMPOUNDS WARNER CHILCOTT COMPANY, LLC (US) 2013-02-07 US disclosed
US-8314081-B2 Bisphosphonate compounds WARNER CHILCOTT COMPANY, LLC (US) 2012-11-20 US disclosed
EP-2493905-A1 BISPHOSPHONATE COMPOUNDS FOR TREATING BONE METABOLISM DISORDERS Warner Chilcott Company, LLC (PR) 2012-09-05 EP disclosed
WO-2011056589-A1 BISPHOSPHONATE COMPOUNDS FOR TREATING BONE METABOLISM DISORDERS WARNER CHILCOTT COMPANY, LLC (US) 2011-05-12 WO disclosed
US-20110098251-A1 BISPHOSPHONATE COMPOUNDS WARNER CHILCOTT COMPANY, LLC (US) 2011-04-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140194389-A1 BISPHOSPHONATE COMPOUNDS BPGM, PPIP5K2, PTEN KMT2A 4240/4885ALDH1A3 3800/4885ALDH1A1 2404/4885
US-20110098251-A1 BISPHOSPHONATE COMPOUNDS BPGM, PPIP5K2, PTEN KMT2A 4240/4885ALDH1A3 3800/4885ALDH1A1 2404/4885
US-20130035482-A1 BISPHOSPHONATE COMPOUNDS BPGM, PPIP5K2, PTEN KMT2A 4240/4885ALDH1A3 3800/4885ALDH1A1 2404/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.